Manage Your Liver
Q:

World Hepatitis Day 2016 - Focus on long term protection after treatment to achieve a 65% reduction in deaths

World Hepatitis Day 2016 - Focus on long term protection after treatment to achieve a 65% reduction in deaths
A:

The World Health Organization’s strategy on viral hepatitis in 2015 estimated that there would be 1.4 million deaths from hepatitis-related diseases in 2016. The mortality rate is very high and the number of deaths is far greater than the sum of deaths from Malaria and HIV [1]. Therefore, one of the main targets of World Hepatitis Day 2016 is to reduce hepatitis-related deaths by 65% by 2030, through improving vaccination, preventing early-life infection and providing universal access to treatment.

 

A 65% reduction is not an easy target and in order to achieve this target by 2030, there is a key factor that cannot be neglected but was not mentioned above: post-treatment recovery and protection.

 

A recent study stated that even after successful eradication of hepatitis C virus and achieving sustained virologic response (SVR), the risk of hepatocellular carcinoma (HCC) or liver cancer remains [2]. Another research conducted by the University of Barcelona pointed out that after receiving treatment, some hepatitis C patients developed HCC and the progression was very fast. Research suspected that this was due to the immune system, and suggested that hepatitis C patients monitor their condition closely after treatment, especially those who had HCC or liver fibrosis previously[3].

 

These results show that the risk of serious liver diseases remains even after successful treatment. In addition, after eliminating the virus, the liver needs to rely on its self-repair ability to produce new liver cells so that normal liver function can resume. Therefore, enhancing liver recovery and protection is an integral part that should be added to the strategy. In order to reduce the number of deaths caused by hepatitis-related diseases by 65% effectively, post-treatment liver protection measures must be improved to ensure the liver’s longevity and lower the risk of death.

 

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Related Questions
A:
With thousands of supplements in the market, and little regulations on supplements, finding a suitable one is difficult enough, let alone finding a SAFE one!   Here we will look at 5 things that you can look for when buying or using supplements, it can help you to avoid risky products and limited the chance of using something unsafe:   1. Look for registrations In some country, there are registration systems on suppl
A:
ALT (Alanine Aminotransferase / SGPT) is a type of enzyme found in liver cells. When the liver cells are functioning normally, the ALT enzymes should be contained within the liver cells.    You can imagine each liver cells as a balloon, and the ALT enzymes are the air inside the balloon. When the balloon is damaged, the air will be released. And when the liver cells is damaged, ALT enzymes are released into the bloodstream, therefore we are able to find out the l
Hit Questions
A:
YHK has significant effect in stopping liver inflammation; it can enhance the recovery of liver health and protect liver cells. Those who have experienced YHK often have these questions in mind: Why is YHK so different from other liver medicines and supplements? Why is it possible to have such unprecedented effects? The answer seems magical, but in fact, it is not complicated - Because YHK possesses a perfect balance.   To explain this, we must first point out that YH
A:
You probably have already heard about the new antiviral hep C drug, which is effective but insanely expensive. It claims to have around 90% success rate, that’s why so many hepatitis C patients are dying for it even though it’s extremely costly. But apart from its expensive price tag, there is a bigger issue behind this new drug that not many people know about. Scientists and researchers have found an increased risk of extreme liver cancer related to this new drug after successful
A:
Hepatitis C is a wide spread and deadly disease affecting an estimated of 3.5 million Americans.   Treatment for hepatitis C has evolved over the years, going from highly toxic drugs involving injections with horrible side effects, to medications with minimal side effects. Success rate of treatment options has also improved greatly Although the high price tag of the new DAA treatment is controversial, it has undoubtedly helped to cure many hepatitis C patients.
A:
“It isn't fat but rather fibrosis that drives disease progression in people with advanced non-alcoholic steatohepatitis (NASH).”   NASH is one of the most prevalent liver diseases nowadays. NASH is related to non-alcoholic fatty liver disease (NAFLD) which is characterized by the buildup of fat in the liver. Although it is normal to have some fat in the liver, some people might develop inflammation because of this fat accumulation, this is cal
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us